May 8, 2024JAMA Network OpenOpen Access

Rapid Initiation of Injection Naltrexone for Opioid Use Disorder

View Full Paper

Ask AI

Bookmark

Authors

MSMatisyahu ShulmanNew York State Department of State MGMiranda GreinerColumbia University Irving Medical Center HTHiwot M. TafessuEmmes (United States)

Discussion

Member takes

Implication

Randomized trial demonstrates rapid initiation increases extended-release naltrexone receipt in opioid use disorder, indicating a viable strategy despite higher adverse events.

Key Points

Rapid initiation of extended-release naltrexone achieved noninferior treatment initiation rates of 62.7% compared with 35.8% for standard procedure in opioid use disorder.
Cluster randomized trial across 6 community inpatient addiction treatment units compared rapid initiation with standard buprenorphine taper in 415 participants.
Supports rapid initiation to expand extended-release naltrexone access in opioid use disorder, although adverse events highlight the need for safety monitoring.

Cite This Study

Shulman et al. (2024) studied this question.

synapsesocial.com/papers/68e6b01bb6db6435876316ee https://doi.org/10.1001/jamanetworkopen.2024.9744

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates rapid initiation increases extended-release naltrexone receipt in opioid use disorder, indicating a viable strategy despite higher adverse events.

Rapid Initiation of Injection Naltrexone for Opioid Use Disorder

Discussion

Member takes

Implication

Key Points

Cite This Study

Rapid Initiation of Injection Naltrexone for Opioid Use Disorder

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider